These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9733674)

  • 21. NGF and anti-transferrin receptor antibody conjugate: short and long-term effects on survival of cholinergic neurons in intraocular septal transplants.
    Granholm AC; Bäckman C; Bloom F; Ebendal T; Gerhardt GA; Hoffer B; Mackerlova L; Olson L; Söderström S; Walus LR
    J Pharmacol Exp Ther; 1994 Jan; 268(1):448-59. PubMed ID: 8301587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system.
    Wu D; Song BW; Vinters HV; Pardridge WM
    J Drug Target; 2002 May; 10(3):239-45. PubMed ID: 12075825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
    Jeong Lee H; Pardridge WM
    J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Soluble expression and target study to brain of anti-TfR ScFv].
    Yan B; Zhu HQ; Huang PT
    Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):342-7. PubMed ID: 15971602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate.
    Li XB; Liao GS; Shu YY; Tang SX
    J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat.
    Moos T; Morgan EH
    J Neurochem; 2001 Oct; 79(1):119-29. PubMed ID: 11595764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
    Huwyler J; Yang J; Pardridge WM
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.
    Schnyder A; Krähenbühl S; Török M; Drewe J; Huwyler J
    Biochem J; 2004 Jan; 377(Pt 1):61-7. PubMed ID: 14516278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor.
    Paris-Robidas S; Emond V; Tremblay C; Soulet D; Calon F
    Mol Pharmacol; 2011 Jul; 80(1):32-9. PubMed ID: 21454448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A narrow time-window for access to the brain by exogenous protein after immunological targeting of a blood-brain barrier antigen.
    N Ghabriel M; J Lu J; Tadros R; Hermanis G
    J Comp Pathol; 2004 Jul; 131(1):52-60. PubMed ID: 15144799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of transferrin receptor in an immortalized cell line of rat brain endothelial cells, RBE4.
    Huwyler J; Froidevaux S; Roux F; Eberle AN
    J Recept Signal Transduct Res; 1999; 19(1-4):729-39. PubMed ID: 10071796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain targeting using novel lipid nanovectors.
    Béduneau A; Hindré F; Clavreul A; Leroux JC; Saulnier P; Benoit JP
    J Control Release; 2008 Feb; 126(1):44-9. PubMed ID: 18055056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein.
    Li JY; Sugimura K; Boado RJ; Lee HJ; Zhang C; Duebel S; Pardridge WM
    Protein Eng; 1999 Sep; 12(9):787-96. PubMed ID: 10506289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence-labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the blood-brain barrier.
    Yue J; Liu S; Wang R; Hu X; Xie Z; Huang Y; Jing X
    Macromol Biosci; 2012 Sep; 12(9):1209-19. PubMed ID: 22807211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.
    Poduslo JF; Curran GL; Sanyal B; Selkoe DJ
    Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.
    Pardridge WM; Kang YS; Buciak JL
    Pharm Res; 1994 May; 11(5):738-46. PubMed ID: 8058646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
    Friden PM; Olson TS; Obar R; Walus LR; Putney SD
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1491-8. PubMed ID: 8819537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.